At a glance
ClinicalIndex Comparison RecordN/ACompleted· 75 enrolled
Drug / intervention
Resolute Onyx Stent - 2.25 mm - 4.0 mmdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting Stent System Medtronic RESOLUTE ONYX Core (2.25 mm - 4.0 mm) Clinical Study
In Brief
A clinical study evaluating Resolute Onyx Stent - 2.25 mm - 4.0 mm for Coronary Artery Disease. Completed, enrolled 75 participants across 12 sites.
Detailed Summary
The purpose of this trial is to assess the safety and efficacy of the Resolute Onyx Zotarolimus-Eluting Coronary Stent System for the treatment of de novo lesions in native coronary arteries with a reference vessel diameter of 2.25 mm to 4.2 mm.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 2015
Enrollment StartJul 2015
Primary CompletionJul 2016
Study CompletionDec 2018
TodayJul 2026
First PostedApr 17, 2015
Enrollment StartJul 7, 2015
Primary CompletionJul 5, 2016
Study CompletionDec 3, 2018
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 11.2 years ago
Interventions
Resolute Onyx Stent - 2.25 mm - 4.0 mmdevice